You can delete your DNA data from 23andMe
People who submitted a DNA sample to 23andMe for genetic testing can get that data deleted, something Washington state officials are highlighting after the company filed for bankruptcy last month.
Why it matters: While the company said it won't change how it protects people's data, it's seeking a buyer — and a new owner could run things differently, making it important for people to know their rights, the Washington state attorney general's office said in a news release.
State of play: A 2023 Washington state law, the My Health My Data Act, requires companies like 23andMe to disclose how they use Washingtonians' health data, while ensuring residents have the right to get their data deleted.
Zoom in: 23andMe customers can delete their data by logging into their account, going to "settings," and scrolling down to the section labeled, "23andMe Data."
If you click "view," you can download your data for your own records if you want.
Then, scroll down to the "Delete Data" section, and click "Permanently Delete Data."
You'll receive an email from 23andMe asking you to confirm your deletion request.
The fine print: You can also choose to have your saliva sample destroyed, by visiting your account settings page and going to "Preferences."
To revoke consent for your genetic data to be used for research, go to your account settings and find "Research and Product Consents."
What they're saying: If 23andMe "for any reason" declines a Washington resident's data deletion request, that person can file a complaint with the state attorney general, the company's website says.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
16 hours ago
- Bloomberg
Bankruptcy Was Good for 23andMe
Sometimes a public company has a controlling shareholder who wants to take it private by buying out all of the other shareholders, and that's always messy. 1 The controlling shareholder will to some extent be negotiating with herself: She will want to buy the company for a low price, but the company's shareholders will want to get a high price, but she's the controlling shareholder and can vote for the low price. There are standard solutions to the problem, but they are only partial solutions: In the past few months, I have written a few times about 23andMe Holding Co. as an illustration of these problems. 23andMe is a publicly traded genetic testing company that was once worth about $6 billion, but it has now fallen on hard times. Its founder, Anne Wojcicki, owns about 49% of the voting power of the stock, making her effectively a controlling shareholder. She offered to buy all the stock she didn't own, to take the company private and fix its problems 'outside of the short term pressures of the public markets.' But the board of directors, whose job was to find an 'actionable proposal that is in the best interests of the non-affiliated shareholders,' didn't think her offer was good enough.
Gizmodo
17 hours ago
- Gizmodo
23andMe Re-Opens Data Auction With $305 Million Bid From Former CEO
After a brief court dispute, 23andMe and all its assets are up for auction once again. The second time around, former CEO Amy Wojcicki has started out hot with an opening bid nearly $50 million higher than the previous auction's winner. Last month, Regeneron Pharmaceuticals purchased the bankrupt 23andMe for $256 million, beating out Wojcicki's nonprofit, TTAM Research Institute's opening bid by over $100 million. However, Wojcicki quickly requested that a U.S. judge reopen the auction. In her filing, Wojcicki argued that 23andMe's advisors capped her maximum bid at $250 million due to concerns about TTAM's 'financial wherewithal.' Now, Wojcicki says she has the additional backing of an unnamed Fortune 500 company valued at over $400 billion. On Wednesday, all parties involved reached a compromise in federal court, according to Bloomberg, which allowed Wojcicki to reopen the process with a $305 million bid. Now, Regeneron can counter with an offer of at least $315 million. After that, Wojcicki gets another bid and then Regeneron can respond with the auction's final offer. The downfall of 23andMe has been fascinating to watch. Once valued at $6 billion, 23andMe filed for bankruptcy in March after its worth plummeted to nearly $0. Pinpointing the exact cause of 23andMe's collapse is hard. You can easily argue that it was inevitable given the limits of its original concept. Although the company tried finding other ways to generate profit, nothing really worked. For example, last year, the Washington Post reported that 23andMe's attempt to launch a subscription service with personalized reports and advice bombed. However, 23andMe's massive 2023 data breach certainly didn't help its survival. Hackers were able to obtain information about 6.9 million people, including names, birth years, relationship labels, family names, and locations. 23andMe took five months to notice the hack, two months to publicly admit its true severity, and even tried placing the blame on customers. (Per Bloomberg, 23andMe is trying to resolve claims from a class action lawsuit related to the data breach as part of the bankruptcy.) Personally, I think it's silly to trust any company within the consumer DNA testing industry. If you have a similar view, you're likely not super affected by 23andMe's bankruptcy. So, you might not care about the ongoing auction. However, the fact that it's even allowed to proceed at all is concerning. What's ultimately up for sale right now is 23andMe's database of over 15 million people's DNA. When the auction was first announced, California's Attorney General urged people to request that 23andMe delete their data and lawmakers opened an investigation stating that with 'the lack of a federal comprehensive data privacy and security law, we write to express our great concern about the safety of Americans' most sensitive personal information.' Under 23andMe's privacy policy, your information is deleted upon request. Whichever bidder wins the auction has agreed to comply with the existing promise. But no one who used 23andMe's products explicitly agreed to be part of this trade deal. The sale of something as sensitive as DNA, which you cannot change like a password or an email address, should require more than implicit consent. In other words, it shouldn't be up to an individual to opt out by requesting their data to be deleted. Without explicit permission from each person in that database, the sale shouldn't be allowed to go on at all.
Washington Post
18 hours ago
- Washington Post
Fate of 23andMe genetic data still not settled amid bankruptcy fight
The fate of genetic data belonging to millions of 23andMe customers is again up in the air, as the bankrupt company seeks a judge's permission to consider another bid from its co-founder and undisclosed financial backers after previously accepting an offer from Regeneron Pharmaceuticals. A nonprofit research institute backed by Anne Wojcicki, 23andMe's co-founder and former CEO, has been pressing 23andMe to consider additional bids purportedly topping Regeneron's $256 million cash offer last month, arguing that the bankruptcy auction was closed prematurely. That has put 23andMe in a bind, with the firm saying in court filings it was it risk of litigation unless it effectively reopened the auction to entertain final offers from Wojcicki's group and Regeneron.
